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Abstract
Chronic intestinal pseudo-obstruction (CIPO) is a syndrome characterized by recurrent clinical episodes of intestinal
obstruction in the absence of any mechanical cause occluding the gut. There are multiple causes related to this rare
syndrome. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is one of the causes related to primary
CIPO. MNGIE is caused by mutations in the gene encoding thymidine phosphorylase. These mutations lead to an accu-
mulation of thymidine and deoxyuridine in blood and tissues of these patients. Toxic levels of these nucleosides induce
mitochondrial DNA abnormalities leading to an abnormal intestinal motility.
Herein, we described two rare cases of MNGIE syndrome associated with CIPO, which needed surgical treatment
for gastrointestinal complications. In one patient, intra-abdominal hypertension and compartment syndrome gener-
ated as a result of the colonic distension forced to perform emergency surgery. In the other patient, a perforated
duodenal diverticulum was the cause that forced to perform surgery. There is not a definitive treatment for MNGIE
syndrome and survival does not exceed 40 years of age. Surgery only should be considered in some selected
patients.
Background
Intestinal pseudo-obstruction is a rare and highly morbid
syndrome characterized by impaired gastrointestinal pro-
pulsion together with symptoms and signs of bowel
obstruction in the absence of any lesions occluding the
gut lumen [1]. Pseudo-obstructive syndromes may be
either acute (due to abdominal surgery, retroperitoneal
haemorrhage, spinal or pelvic trauma, myocardial infarc-
tion, or hypokalemia) or, more commonly, chronic. The
latter form, that is, chronic intestinal pseudo-obstruction
(CIPO) is an important cause of chronic functional
intestinal failure. CIPO can be further classified as either
“secondary” t oaw i d ea r r a yo fr e c o g n i z e dp a t h o l o g i c a l
conditions or “idiopathic” [2]. The diagnosis of CIPO is
mainly clinical and confirmed by endoscopic or radiologi-
cal exclusion of mechanical causes as well as by evidence
of air-fluid levels in distended bowel loops [3]. There are
multiple causes related to this rare syndrome. Mitochon-
drial neurogastrointestinal encephalomyopathy (MNGIE)
is one of the syndromes related to CIPO. The clinical
diagnosis of MNGIE disease is based on the presence of
severe gastrointestinal dysmotility, cachexia, ptosis, exter-
nal ophthalmoplegia, sensorimotor neuropathy, asympto-
matic leukoencephalopathy as observed on brain
magnetic resonance imaging (MRI), and family history
consistent with autosomal recessive inheritance [4].
Direct evidence of MNGIE disease is provided by one of
the following findings: increase in plasma thymidine
(dThd) concentration greater than 3 μmol/l and increase
in plasma deoxyuridine (dUrd) concentration greater
than 5 μmol/l [5]. Thymidine phosphorylase (TP) enzyme
activity in leukocytes is less than 10% of the control
mean. Molecular genetic testing of TYMP,t h eg e n e
encoding thymidine phosphorylase, detects mutations in
approximately 100% of affected individuals [6]. Visceral
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tract so surgery has a limited role in the treatment of
these patients.
We described two rare cases of MNGIE syndrome
associated with CIPO, which needed surgical treatment
for gastrointestinal complications.
Case reports
Case 1
A 27 year old woman with a history of frequent epi-
sodes of intestinal pseudo-obstruction since she was
3 years old. The patient was diagnosed in the early
childhood of esophageal achalasia and urinary problems
due to a lack of muscular contractility. Neurological
examination revealed ptosis and external ophthalmople-
gia, distal muscle weakness and lower limb hypoesthesia.
Deep tendon reflexes were absent in the lower limbs.
A brain MRI showed a white matter demyelinization.
Laboratory tests demonstrated a low TP activity in the
buffy coat associated with an increased concentration of
plasma dThd (8.3 μmol/l) and dUrd (11.3 μmol/l), con-
firming the diagnosis of MNGIE syndrome. Clinical epi-
sodes of pain, abdominal distension and diarrhea have
limited the oral intake of the patient and at the age of
18 years old she had a body mass index (BMI) of
16.2 Kg/m
2. Oral vitamin E, coenzyme Q10, cisapride
and oral erythromycin were ineffective in improving
neurological and digestive symptoms. Home parenteral
nutrition was started with several episodes of catheter-
related sepsis that required admission. During the last
hospitalization, the patient presented a new clinical epi-
sode of intestinal pseudo-obstruction that did not
improve with medical treatment (nasogastric and rectal
tubes, serum therapy, antibiotherapy and prokinetics).
An abdominal computed tomography (CT) showed dila-
tation of the colon and exclusion of mechanical causes
(Figure 1). Intra-abdominal hypertension and compart-
ment syndrome generated as a result of the colonic dis-
tension forced to perform emergency surgery. A
subtotal colectomy with ileostomy was performed
(Figure 2). The patient was discharged in a clinically
acceptable state on postoperative day 12. The histologi-
cal study showed atrophy and focal fibrosis of the mus-
cularis propria with preservation of enteric plexus.
Case 2
A 22 year old woman with a gastrostomy since early
childhood due to oral intolerance and progressive
gastrointestinal dysmotility with vomiting, dysphagia,
episodic abdominal pain and distension. Neurological
examination revealed bilateral external ophthalmoplegia,
ptosis, absent tendon reflexes and lower limb hypoesthe-
sia. Prokinetics and oral vitamin E supplementation
did not improve digestive and neurological symptoms.
Diagnostic studies including a colonoscopy ruled out
mechanical causes of obstruction and a diagnosis of
MNGIE had been made on the basis of an increased
levels of dThd (9.3 μmol/l and dUrd (12.7 μmol/l) in
plasma. The patient had also been diagnosed of small
bowel diverticula. Because of severe malnutrition with a
BMI of 11.2 Kg/m
2, home parenteral nutrition was
started. At the age of 18 years a colectomy with ileost-
omy was performed due to a colonic perforation sec-
ondary to an acute episode of CIPO. Two years later,
and after the diagnosis of MNGIE syndrome the patient
received an allogeneic hematopoietic stem cell trans-
plantation (HSCT) to slow down the progression of the
disease with good initial response. Six months after
HSCT the patient was readmitted because of a clinical
episode of pain, abdominal distension and fever. An
abdominal CT showed massive pneumoperitoneum due
to perforated duodenal diverticulum. The patient
Figure 1 A, B and C: Axial, sagittal and coronal abdominal CT scan images showing dilated colon.
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was performed. Due to poor general condition and sep-
tic shock secondary to intestinal perforation, the patient
died on postoperative day 12 at the intensive care unit.
Discussion
CIPO is a rare syndrome characterized by dysfunction of
gut propulsive motility which results in a clinical picture
mimicking mechanical obstruction, in the absence of any
mechanical process [1]. Even though CIPO is a rare
syndrome, it represents up to 15% and 20% of the causes
of chronic intestinal failure in children and adults, respec-
tively [7]. Etiology may be multiple but CIPO is idiopathic
in the majority of cases. Primary cases of CIPO are due to
intrinsic alterations of the components of gastrointestinal
wall while other cases are secondary to a variety of
diseases (neurological, immune-mediated and collagen dis-
eases, endocrine diseases) and drugs (clonidine, phenothia-
zines, antidepressants, antiparkinsonians, antineoplastics,
bronchodilators, anthraquinones). Histopathological find-
ings of primary CIPO include abnormalities affecting the
smooth muscle cells (visceral myopathies), enteric neu-
rones (visceral neuropathies) and interstitial cells of Cajal
(mesenchymopathies) [8,9].
MNGIE is an autosomal recessive syndrome due to
mutations in the TP gene and it is characterized by
severe gastrointestinal dysmotility, cachexia, ptosis,
ophthalmoparesis, peripheral neuropathy, white matter
changes in brain magnetic resonance imaging and mito-
chondrial abnormalities [4]. MNGIE is the most fre-
quent mitochondrial encephalomyopathy associated with
CIPO. Deficiency of thymidine phosphorylase results in
elevated concentrations of thymidine (dThd) and deox-
yuridine (dUrd) in blood and tissues, as seen in our
patients. Toxic levels of dThd and dUrd induce abnorm-
alities of mitochondrial DNA (mtDNA) affecting the
enzymes involved in oxidative phosphorylation. Severe
depletion of mtDNA in smooth muscle cells of gastroin-
testinal tract and vascular wall is the most striking
molecular defect of MNGIE patients [10].
Although clinical manifestations are homogeneus and
recognizable, MNGIE is often misdiagnosed, particularly
early in the course of the disease before all of the clinical
manifestations are apparent. Gastrointestinal dysmotility is
the most common presenting symptom [5]. Gastrointest-
inal features including dysphagia, gastroparesis, recurrent
episodes of intestinal pseudo-obstruction and chronic
diarrhea were confirmed in our patients. Small bowel
diverticula were reported in 53% of MNGIE patients in a
previous report [11]. Urinary symptoms, generally asso-
ciated with evidence of urinary tract distension, are also
common [9]. These two last clinical findings were seen in
the cases reported here. Although myogenic involvement
is more frequent, visceral abnormalities in gastrointestinal
wall may be myogenic, neurogenic or both. Examination
of full-thickness biopsies of the intestinal wall may help in
distinguish between a myogenic or neurogenic mechanism
[9,10]. Neurological signs and symptoms included periph-
eral polyneuropathy, leukoencephalopathy, ptosis, progres-
sive ophtalmoplegia and hearing loss, as seen in our
patients. This cluster of signs and symptoms is very speci-
fic. Other neurological symptoms are infrequent [4].
Mitochondrial dysfunction and clinical symptoms are
produced after years of cumulative toxic effects of exces-
sive nucleosides on mtDNA. Different mechanisms have
been proposed to reduce circulating nucleosides as a pos-
sible therapy for MNGIE [12]. While hemodialysis to
reduce nucleoside levels does not seem to be effective, pla-
telet infusions transiently provide TP activity and reduce
plasma dThd and dUrd levels [13]. Other mechanisms
proposed to restore circulating TP levels are the direct
administration of the stabilized active TP protein or intro-
duction of the functional gene through viral vectors.
Several drugs have been tried in the treatment of
Figure 2 A: Intraoperative picture showing dilated colon; B: Subtotal colectomy specimen with loss of colonic haustras.
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vitamin C or carnitine but data on their clinical efficiency
are lacking [13,14]. To restore TP activity, allogeneic
hematopoietic stem cell transplantation (HSCT) has been
proposed as a treatment for patients with MNGIE obtain-
ing encouraging results [15]. This therapeutic approach
was performed in the case 2, with good initial clinical
response. Standardization of the transplant protocol will
allow evaluation of the safety and efficacy of HSCT for
patients with MNGIE [16].
As seen in our patients, the clinical course of CIPO
entails a progressive deterioration of bowel function and
d i g e s t i v es y m p t o m s .T h ed i f f i c u l t yo fo r a li n t a k eo f t e n
leads to severe malnutrition that, in most cases required
long-term parenteral nutrition. The main limitations of
this nutritional support include liver insufficiency, pan-
creatitis, glomerulonephritis and catheter-related compli-
cations (septicemia or thrombosis). Primary CIPO due to
MNGIE syndrome has a particularly poor prognosis and
patients usually die around 40 years of age [17].
Pharmacological treatment of CIPO includes antie-
metics, prokinetics, antispasmodics, laxatives or antidiar-
rheal and analgesic. Antibiotics are often useful to
contrast bacterial overgrowth. As demonstrated in our
patients, surgery is one of the mainstay of CIPO treat-
ment but it has to be considered only in some carefully
selected patients. A history of multiple and useless sur-
geries are typical of the syndrome because of the mis-
leading digestive clinical manifestations. Benefits of
surgical resections are temporally because CIPO is a
progressive disease and involves the whole alimentary
tract. In fact, surgery can precipitate clinical deteriora-
tion of patients. Indications for surgery must be appro-
priate and excessive number of surgical procedures
must be avoided. Enterostomies seem to be the most
logical approach in most cases. Terminal ileostomy
improves digestive symptoms, decreases abdominal dis-
tension and facilitates the absorption of nutrients [9,18].
Intestinal or multivisceral transplantation should be
considered when all other treatment options have failed.
The complications related to this procedure such as
bacterial infections are frequent and mortality rate
approaches 50% at 5 years [19]. The main causes of
dead in CIPO are related to parenteral nutrition, sur-
gery, post-transplantation and septic shock of gastroin-
testinal origin [9].
Conclusion
Although surgery has a limited role in the management
of MNGIE patients with secondary CIPO, emergency
surgery may be necessary in patients with digestive
complications.
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